Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer

Completed

Conditions studied: Metastatic Breast Cancer

In brief

We are trying to develop better ways to detect when cancer therapies are working.

Key facts

Study ID

NCT00156273

Run by

University of Michigan Rogel Cancer Center

People needed

69

Starts

2005-04-01

Expected to finish

2008-10-01

Last updated by the study team

2017-07-05

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Females at least 18 years of age 2 Diagnosis of metastatic breast cancer 3.ECOG Score of 0-2 4.Treating oncologist has decided to initiate any new systemic therapy with emphasis on recruiting patients commencing a taxane-based regimen. Taxine-based therapy may be docetaxel or paclitaxel, and it can be given on any schedule,including weekly or every 3 weeks. Other treatment can include non-taxane chemotherapy or trastuzumab-with or without other therapy.
• Patient is willing to return for one or more additional \~18 mL blood draw (s) at 24-48-, and /or 72 hours and \~3-4 weeks after the initiation of therapy.At a minimum, patients must donate blood at baseline, one intermediate interval (24, 48, 72 hr) and at \~3-4 weeks 6.Signed Informed Consent Form

You may not qualify if…

• Patient is unable and unwilling to provide a blood specimen at a minimum of one of the intermediate blood draw time points at 24, 48, or 72 hours -

Where it is running

• University of Michigan Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.